Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis

Journal of Neuro-Oncology

Volumn 118, Issue 2, 2014, Pages 277-287

  Grube, Susanne ^a   Dünisch, Pedro ^a   Freitag, Diana ^a   Klausnitzer, Maren ^a   Sakr, Yasser ^a   Walter, Jan ^a   Kalff, Rolf ^a   Ewald, Christian ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Brain tumor; FASN; Fatty acid synthesis; Glioma; Orlistat

Indexed keywords

ANTINEOPLASTIC AGENT; C 75; CASPASE 3; CERULENIN; FATTY ACID; FATTY ACID SYNTHASE; KI 67 ANTIGEN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; 4-METHYLENE-2-OCTYL-5-OXOFURAN-3-CARBOXYLIC ACID; CASP3 PROTEIN, HUMAN; FASN PROTEIN, HUMAN; FATTY ACID SYNTHASE INHIBITOR; GAMMA BUTYROLACTONE; LACTONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTOMA; AUTOPHAGY; CANCER CELL LINE; CANCER GRADING; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GLIOBLASTOMA; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN NEOPLASMS; CELL CULTURE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TISSUE CULTURE TECHNIQUE; TUMOR CELL LINE;

4-BUTYROLACTONE; APOPTOSIS; AUTOPHAGY; BRAIN; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CERULENIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACID SYNTHASE, TYPE I; FATTY ACID SYNTHESIS INHIBITORS; GLIOBLASTOMA; GLIOMA; HUMANS; LACTONES; NEOPLASM GRADING; TISSUE CULTURE TECHNIQUES;

EID: 84903903699     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1452-z     Document Type: Article

References (46)

1. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479-489
2. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9-21. doi: 10.1002/ana.22425
3. Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66:5977-5980. doi: 10.1158/0008-5472.CAN-05-4673
4. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763-777. doi: 10.1038/nrc2222
5. Zhao W, Kridel S, Thorburn A, Kooshki M, Little J, Hebbar S, Robbins M (2006) Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 95:869-878. doi: 10.1038/sj.bjc.6603350
6. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2: ra82 doi: 10.1126/scisignal.2000446
7. Tao BB, He H, Shi XH, Wang CL, Li WQ, Li B, Dong Y, Hu GH, Hou LJ, Luo C, Chen JX, Chen HR, Yu YH, Sun QF, Lu YC (2013) Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J Clin Neurosci 20:717-720. doi: 10.1016/j.jocn.2012.03.050
8. Maier T, Leibundgut M, Boehringer D, Ban N (2010) Structure and function of eukaryotic fatty acid synthases. Q Rev Biophys 43:373-422. doi: 10.1017/S0033583510000156
9. Kusakabe T, Maeda M, Hoshi N, Sugino T, Watanabe K, Fukuda T, Suzuki T (2000) Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem 48:613-622
10. Kersten S (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2:282-286. doi: 10.1093/embo-reports/kve071
11. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM (1998) Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101:1-9. doi: 10.1172/JCI1411
12. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2002) Role of the phosphatidylinositol 3-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642-646
13. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80-90
14. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707-715
15. Cerne D, Zitnik IP, Sok M (2010) Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity. Arch Med Res 41:405-409. doi: 10.1016/j.arcmed.2010.08.007
16. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS (2008) Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 26:5713-5720. doi: 10.1200/JCO.2008.18.2675
17. Kusakabe T, Nashimoto A, Honma K, Suzuki T (2002) Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 40:71-79
18. Jiang B, Li EH, Lu YY, Jiang Q, Cui D, Jing YF, Xia SJ (2012) Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer. Urology 80: 484 e489-415 doi: 10.1016/j.urology.2012.02.046
19. Makino K, Nakamura H, Hide T, Yano S, Kuroda J, Iyama K, Kuratsu J (2012) Fatty acid synthase is a predictive marker for aggressiveness in meningiomas. J Neurooncol 109:399-404. doi: 10.1007/s11060-012-0907-3
20. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP (2000) Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2379-2381
21. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64:2070-2075
22. Westphal M, Nausch H, Zirkel D (1996) Cell culture of human brain tumors on extracellular matrices: methodology and biological applications. Methods Mol Med 2:81-99. doi: 10.1385/0-89603-335-X:81
23. Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C (2010) Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol 12:844-854. doi: 10.1093/neuonc/noq004
24. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
25. Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HC, Castilho RF, Coletta RD, Vercesi AE, Graner E (2011) Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Invest 91:232-240. doi: 10.1038/labinvest.2010.157
26. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, Schulze A (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24:6465-6481. doi: 10.1038/sj.onc.1208802
27. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24:3574-3582. doi: 10.1038/sj.onc.1208463
28. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474-482. doi: 10.1002/(SICI)1097- 0142(19960201)77:3<474:AID-CNCR8>3.0.CO;2-K
29. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, Grizzle WE (2000) The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 31:1068-1073. doi: 10.1053/hupa.2000.9842
30. Liu H, Liu JY, Wu X, Zhang JT (2010) Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 1:69-89
31. Knowles LM, Yang C, Osterman A, Smith JW (2008) Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 283:31378-31384. doi: 10.1074/jbc.M803384200
32. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97:3450-3454. doi: 10.1073/pnas.050582897
33. Vance D, Goldberg I, Mitsuhashi O, Bloch K (1972) Inhibition of fatty acid synthetases by the antibiotic cerulenin. Biochem Biophys Res Commun 48:649-656
34. Lookene A, Skottova N, Olivecrona G (1994) Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Eur J Biochem 222:395-403
35. Browne CD, Hindmarsh EJ, Smith JW (2006) Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. Faseb J 20:2027-2035. doi: 10.1096/fj.05-5404com
36. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ (2007) Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 67:1262-1269. doi: 10.1158/0008-5472.CAN-06-1794
37. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G (2003) Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302:898-903
38. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R (2009) Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun 385:454-459. doi: 10.1016/j.bbrc.2009.05.085
39. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26:756-784. doi: 10.1101/gad.187922. 112
40. Hill MM, Feng J, Hemmings BA (2002) Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 12:1251-1255
41. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR (2002) Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62:2227-2231
42. Kant S, Kumar A, Singh SM (2014) Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta 1840:294-302. doi: 10.1016/j.bbagen.2013.09.020
43. Paumen MB, Ishida Y, Han H, Muramatsu M, Eguchi Y, Tsujimoto Y, Honjo T (1997) Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Biochem Biophys Res Commun 231:523-525. doi: 10.1006/bbrc.1997.6089
44. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604-616. doi: 10.1038/nrc1411
45. Knowles LM, Smith JW (2007) Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genom 8:168. doi: 10.1186/1471-2164-8-168
46. Tomek K, Wagner R, Varga F, Singer CF, Karlic H, Grunt TW (2011) Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res 9:1767-1779. doi: 10.1158/1541-7786.MCR-10-0467